Figure 3. Sangivamycin is more potent against the Delta variant of SARS-CoV-2 than remdesivir.

Sangivamycin’s antiviral activity compared with remdesivir using SARS-CoV-2 MOIs and sampling time points as detailed in Table 1 for SARS-CoV-2 variant B.1.617.2 (Delta) in Vero E6/TMPRSS2 (A) and Calu-3 (B) cells. Results are reported as percentage inhibition relative to untreated controls (blue values for sangivamycin, yellow values for remdesivir). Each dose was run in triplicate with error bars representing SDs. IC₅₀, half-maximal inhibitory concentration (lower dotted line); IC₉₀, 90% inhibitory concentration (upper dotted line).